Recently, serumHER2 ECD level of patients detected by enzyme-linked immunoabsorbent assay(ELISA) has been shown to predict tumor HER2 status and reveal its associationwith tumor progression, recurrence and poor prognosis. Here, ERBB2 is linked to neoplasm.